MedTrace Logo

Vitamin K and Cognition in Coronary Heart Disease (NutriCog)

NCT06855953 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-03-04

No results posted yet for this study

Summary

The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)

Conditions

Interventions

DIETARY_SUPPLEMENT

Vitamin K

Participants receive 0.5 mg/day phylloquinone orally for 12 weeks

DIETARY_SUPPLEMENT

Placebo

Participants receive daily placebo for 12 weeks

Sponsors & Collaborators

  • Montreal Heart Institute

    lead OTHER

Principal Investigators

  • Guylaine Ferland, PhD · Université de Montréal

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-17
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06855953 on ClinicalTrials.gov